Ravi Salgia, MD, PhD

City of Hope's Dr Ravi Salgia urges fellow oncologists to refer eligible patients to a new national trial predicting immunotherapy success in NSCLC.

Ravi Salgia, MD, PhD, explains the goals of IMMUNO-BIOMAP, a phase 2 trial identifying biomarkers to predict immunotherapy response in NSCLC.

City of Hope's Dr Ravi Salgia on what it would truly take to cure stage IV non–small cell lung cancer and where oncology is headed next in the years ahead.

City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non–small cell lung cancer.

Ravi Salgia, MD, PhD, discusses how to address and treat transformation from non–small cell lung cancer to small cell lung cancer.

Ravi Salgia, MD, PhD, discusses the ways in which oncologists can watch out for non-small cell lung cancer that transforms to small-cell lung cancer.

Ravi Salgia, MD, PhD, discusses the results from a study of LB-100 combined with chemotherapy or immunotherapy to address transformation from non-small cell lung cancer to small cell lung cancer.